No description available.

In cultured rat hepatocytes the key gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PCK) is known to be induced by glucagon via an elevation of cAMP. Prostaglandin E₂ has been shown to antagonize the glucagon-activated cAMP formation, glycogen phosphorylase activity and glucose output in hepatocytes. It was the purpose of the current investigation to study the potential of PGE₂ to inhibit the glucagon-induced expression of PCK on the level of mRNA and enzyme activity. PCK mRNA and enzyme activity were increased by 0.1 nM glucagon to a maximum after 2 h and 4 h, respectively. This increase was completely inhibited if 10 μM PGE2 was added concomitantly with glucagon. This inhibition by PGE₂ of glucagon-induced PCK activity was abolished by pertussis toxin treatment. When added at the maximum of PCK mRNA at 2 h, PGE₂ accelerated the decay of mRNA and reduced enzyme activity. This effect was not reversed by pertussis toxin treatment. Since in liver PGE₂ is derived from Kupffer cells, which play a key role in the local inflammatory response, the present data imply that during inflammation PGE₂ may reduce the hepatic gluconeogenic capacity via a Gᵢ-linked signal chain.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22355号 / 医博第4596号 / 新制||医||1042(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 萩原 正敏, 教授 岩田 想, 教授 濵﨑 洋子 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

<p>Degradation of mRNA is a highly regulated step important for proper gene expression. Degradation of eukaryotic mRNA is initiated by shortening of the 3’ end located poly(A) tail. Poly(A)-specific ribonuclease (PARN) is an oligomeric enzyme that degrades the poly(A) tail with high processivity. A unique property of PARN is its ability to interact not only with the poly(A) tail but also with the 5’ end located mRNA cap structure. A regulatory role in protein synthesis has been proposed for PARN based on its ability to bind the cap that is required for efficient initiation of eukaryotic mRNA translation. Here we have investigated how the cap structure influences PARN activity and how PARN binds the cap. We show that the cap activates PARN and enhances the processivity of PARN. Further we show that the cap binding complex (CBC) inhibits PARN activity through a protein-protein interaction. To investigate the cap binding property of PARN, we identified the cap binding site at the molecular level using site-directed mutagenesis and fluorescence spectroscopy. We identified tryptophan 475, located within the RNA recognition motif (RRM) of PARN, as crucial for cap binding. A crystal structure of PARN bound to cap revealed that cap binding is mediated by the nuclease domain and the RRM of PARN. Tryptophan 475 binds the inverted 7-Me-guanosine residue through a stacking interaction. Involvement of the nuclease domain in cap binding suggests that the cap site and the active site overlap. Mutational analysis showed that indeed amino acids involved in cap binding are crucial for hydrolytic activity of PARN. Taken together, we show that PARN is an allosteric enzyme that is activated by the cap structure and that the allosteric cap binding site in one PARN subunit corresponds to the active site in the other PARN subunit.</p>

Messenger RNA degradation is crucial for the regulation of eukaryotic gene expression. It not only modulates the basal mRNA levels but also functions as a quality control system, thereby controlling the availability of mRNA for protein synthesis. In Saccharomyces cerevisiae, the first and the rate-limiting step in the process of mRNA degradation is the shortening of the poly(A) tail by deadenylation complex. After the poly(A) tail shortens, mRNA can be degraded either through the major 5' to 3' decapping dependent or the 3' to 5' exosome-mediated degradation pathway. In this thesis, we show some of the means by which mRNA decay factors can modulate gene expression. First, Pat1 is a major cytoplasmic mRNA decay factor that can enter the nucleus and nucleo-cytoplasmically shuttle.  Recent evidence suggested several possible nuclear roles for Pat1. We analyzed them and showed that Pat1 might not function in pre-mRNA decay or pre-mRNA splicing, but it is required for normal rRNA processing and transcriptional elongation. We show that the mRNA levels of the genes related to ribosome biogenesis are dysregulated in the strain lacking Pat1, a possible cause of the defective pre-rRNA processing. In conclusion, we theorize that Pat1 might regulate gene expression both at the level of transcription and mRNA decay. Second, Edc3 and Lsm4 are mRNA decapping activators and mRNA decay factors that function in the assembly of RNA granules termed P bodies. Mutations in mRNA degradation factors stabilize mRNA genome-wide or stabilize individual mRNAs. We demonstrated that paradoxically, deletion of Edc3 together with the glutamine/asparagine-rich domain of Lsm4 led to a decrease in mRNA stability. We believe that the decapping activator Edc3 and the glutamine/asparagine-rich domain of Lsm4 functions together, to modify mRNA decay pathway by altering cellular mRNA decay protein abundance or changing the mRNP composition or by regulating P bodies, to enhance mRNA stability. Finally, mRNA decay was recently suggested to occur on translating ribosomes or within P bodies. We showed that mRNA degradation factors associate with large structures in sucrose density gradients and this association is resistant to salt and sensitive to detergent. In flotation assay, mRNA decay factors had buoyancy consistent with membrane association, and this association is independent of stress, translation, P body formation or RNA. We believe that such localization of mRNA degradation to membranes may have important implications in gene expression. In conclusion, this thesis adds to the increasing evidence of the importance of the mRNA degradation factors in the gene expression.

Degradation of mRNA is a highly regulated step important for proper gene expression. Degradation of eukaryotic mRNA is initiated by shortening of the 3’ end located poly(A) tail. Poly(A)-specific ribonuclease (PARN) is an oligomeric enzyme that degrades the poly(A) tail with high processivity. A unique property of PARN is its ability to interact not only with the poly(A) tail but also with the 5’ end located mRNA cap structure. A regulatory role in protein synthesis has been proposed for PARN based on its ability to bind the cap that is required for efficient initiation of eukaryotic mRNA translation. Here we have investigated how the cap structure influences PARN activity and how PARN binds the cap. We show that the cap activates PARN and enhances the processivity of PARN. Further we show that the cap binding complex (CBC) inhibits PARN activity through a protein-protein interaction. To investigate the cap binding property of PARN, we identified the cap binding site at the molecular level using site-directed mutagenesis and fluorescence spectroscopy. We identified tryptophan 475, located within the RNA recognition motif (RRM) of PARN, as crucial for cap binding. A crystal structure of PARN bound to cap revealed that cap binding is mediated by the nuclease domain and the RRM of PARN. Tryptophan 475 binds the inverted 7-Me-guanosine residue through a stacking interaction. Involvement of the nuclease domain in cap binding suggests that the cap site and the active site overlap. Mutational analysis showed that indeed amino acids involved in cap binding are crucial for hydrolytic activity of PARN. Taken together, we show that PARN is an allosteric enzyme that is activated by the cap structure and that the allosteric cap binding site in one PARN subunit corresponds to the active site in the other PARN subunit.

Les P-bodies sont des granules cytoplasmiques de fonction inconnue. Ils sont néanmoins conservés de la levure à l’homme, suggérant un rôle important chez les eucaryotes. L’analyse de l’influence de l’expression de certaines protéines pouvant se localiser dans ces granules a permis de mettre en évidence le rôle crucial de DDX6 dans l’assemblage des P-bodies. En effet, l’inhibition de l’expression de DDX6 dans les cellules humaines empêche l’assemblage des P-bodies. L’étude de la protéine DDX6 semblait donc être un bon point de départ pour comprendre d’avantage le rôle des P-bodies. Cette hélicase à motif DEAD de 54 kDa interagit avec des protéines du complexe répression de la traduction CPEB chez le Xénope, mais également avec des protéines des complexes de dégradation 5’-3’ et 3’-5 ‘ des ARNm chez les mammifères, les levures et les drosophiles, ou encore avec les protéines Argonautes du complexe miRISC chez les mammifères. Nos travaux se sont donc intéressés à déterminer les principales fonctions de DDX6 dans les cellules humaines. Les complexes protéiques contenant DDX6 ont été purifiés à partir de lysats cytoplasmiques de cellules HEK293 transfectées avec un plasmide codant pour la protéine FLAG-DDX6-HA. Plus de 300 partenaires protéiques ont été identifiés en spectrométrie de masse. Trois complexes majeurs contenant DDX6 ont été mis en évidence : un complexe de répression « CPEB-like », le complexe de décoiffage des ARNm, et un complexe contenant les ataxin-2 et ataxin-2-like. Les protéines du cœur du complexe de jonction d’exons sont également en interaction avec DDX6, suggérant que DDX6 interagit avec des ARNm tout juste sortis du noyau. Enfin, le grand nombre et les hauts scores avec lesquels ont été identifiés les protéines ribosomales nous ont conduit à analyser la présence de DDX6 au niveau des polysomes. L’analyse de lysats cytoplasmiques sur gradient de sucrose nous a permis de mettre en évidence l’association d’une fraction de DDX6 aux polysomes. Toutes ces observations mettent en évidence le rôle multiple de DDX6 entre répression et dégradation des ARNm, dans les cellules humaines. L’hélicase pourrait permettre le recrutement du complexe de répression par des ARNm activement traduits. La fixation multiple de DDX6 à l’ARNm pourrait être un moyen de recruter simultanément les complexes de répression et de dégradation des ARNm sur un même ARNm. / P-bodies are cytoplasmic granules. Their function is unknown, but they are conserved from the yeast to humans, suggesting an important role through eukaryotes. The expression inhibition of several proteins localized in P-bodies leads to their disassembly. In most cases, a cellular stress induced by arsenite treatment causes P-body assembly, except in cells depleted for DDX6. Since this observation showed that DDX6 is necessary for P-body assembly, to study this protein is a good starting point to further understand the role of P-bodies. This 54 kDa DEAD-box helicase interacts with proteins of the CPEB repression complex in xenopus oocytes, but also with protein of the déadénylation and dacapping complex in yeasts, drosophila and mammals, and with proteins of the miRISC complex. Our project was to determine the DDX6 main protein partners in human cells. To do so, DDX6 containing complexes were purified using HEK293 cells transfected with a plasmid encoding for the FLAG-DDX6-HA. Over 300 partners were identified by mass spectrometry. Three main DDX6 containing complexes were highlighted in human cells: A “CPEB-like” repression complex, the decapping complex, and a complex containing ATXN2 and ATXN2L proteins. Exon junction complex core proteins were also identified as DDX6 partners, raising the possibility that DDX6 interacts with mRNA not yet translated. A large number of ribosomal proteins were also identified with high scores, suggesting that DDX6 interacts with actively translated mRNA. Analyze of cytoplasmic lysates on sucrose gradients showed that DDX6 is partially associated with polysomes. To conclude, these observations showed the multiple roles of DDX6 in human cell, between mRNA repression and degradation. The helicase could allow the recruitment of the repression complex on actively translated mRNA. In a nutshell, the multiple binding of DDX6 on one mRNA could be a way to enable the fixation of repression and degradation complexes at the same time, on the same mRNA.

京都大学 / 0048 / 新制・課程博士 / 博士(生命科学) / 甲第21228号 / 生博第397号 / 新制||生||52(附属図書館) / 京都大学大学院生命科学研究科高次生命科学専攻 / (主査)教授 朝長 啓造, 教授 藤田 尚志, 教授 野田 岳志 / 学位規則第4条第1項該当 / Doctor of Philosophy in Life Sciences / Kyoto University / DFAM

No description available.

No description available.